Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Sunday morning. The brokerage issued a sell rating on the stock.

Other analysts have also recently issued research reports about the company. Maxim Group cut their target price on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research report on Tuesday, March 26th. Roth Mkm reiterated a buy rating and set a $40.00 target price on shares of Moleculin Biotech in a research report on Friday, April 12th.

Moleculin Biotech Stock Up 7.0 %

NASDAQ MBRX opened at $4.60 on Friday. Moleculin Biotech has a 52 week low of $4.28 and a 52 week high of $15.75. The stock’s 50-day moving average price is $6.87 and its 200-day moving average price is $8.08. The company has a market capitalization of $10.26 million, a P/E ratio of -0.34 and a beta of 1.96.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned about 0.17% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.